Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12505776 | 1.00 | NOTUM (0.40) | NOTUMARKEAP1S1PR1ALDH1A1 | |
| SCHEMBL3609693 | 0.98 | NOTUM (0.41) | NOTUMARPDE3BPDE3A | |
| SCHEMBL605920 | 0.83 | ASIC3 (0.43) | ALDH1A1MAPK1PDE3BPDE3A | |
| SCHEMBL3603722 | 0.83 | AKR1C3 (0.46) | NOTUMS1PR1ALDH1A1PDE3BPDE3A | |
| SCHEMBL16719169 | 0.83 | NCF1 (0.45) | ALDH1A1 | |
| SCHEMBL27677143 | 0.81 | KMT2A (0.41) | ALDH1A1PDE3BPDE3A | |
| SCHEMBL18039581 | 0.80 | CHRM4 (0.39) | ALDH1A1GAA | |
| SCHEMBL1899796 | 0.77 | ALDH1A1 (0.42) | KEAP1ALDH1A1GAAHTTMAPK1 | |
| SCHEMBL1899800 | 0.77 | ALDH1A1 (0.42) | KEAP1ALDH1A1GAAHTTMAPK1 | |
| SCHEMBL606783 | 0.76 | NPSR1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2489660-A1 | Methods for making central nervous system agents that are TRPV1 antagonists | Abbott Laboratories (US) | 2012-08-22 | — | — | EP | disclosed |
| US-8232411-B2 | Methods for making central nervous system agents that are TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2323989-A2 | METHODS FOR MAKING CENTRAL NERVOUS SYSTEM AGENTS THAT ARE TRPV1 ANTAGONISTS | Abbott Laboratories (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100016611-A1 | METHODS FOR MAKING CENTRAL NERVOUS SYSTEM AGENTS THAT ARE TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2009117626-A2 | METHODS FOR MAKING CENTRAL NERVOUS SYSTEM AGENTS THAT ARE TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-09-24 | — | — | WO | disclosed |
| EP-1660455-B1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1660455-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2006-05-31 | — | — | EP | disclosed |
| US-6933311-B2 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2005-08-23 | — | — | US | disclosed |
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES | 2005-05-26 | — | — | US | disclosed |
| WO-2005016890-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016611-A1 | METHODS FOR MAKING CENTRAL NERVOUS SYSTEM AGENTS THAT ARE TRPV1 ANTAGONISTS | TRPV1, TRPV2, OPRL1 | NOTUM 3148/4885AR 516/4885KEAP1 604/4885 |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | NOTUM 4317/4885AR 267/4885KEAP1 1690/4885 |
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, TMEM109, VIPR1 | NOTUM 4338/4885AR 245/4885KEAP1 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.